TITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
DIFIED) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)

Attorney Docket No.	50059/005002
Serial No.	09/762,577
Applicant	Glenn Dranoff et al.
Filing Date	February 7, 2001
Group	Not Yet Assigned
IDS Filed	March 7, 2001
Customer No.	21559

Sheet 1 of 1

TRADEMARK OFFICE
(37 C F R §1 98(b))

U.S. PATENTS

Examiner's Initials	Document Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT APPLICATION OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

Examiner's Initials	
MD	Dranoff et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," Proc. Natl. Acad. Sci. U.S.A. 90:3539-3543, 1993.
	Dranoff et al., "A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor," Human Gene Therapy 7:111-123, 1997.
	Ellem et al., "A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy," Cancer Immunol. Immunother. 44:10-20, 1997.
	Jäger et al., "Strategies for the development of vaccines to treat breast cancer, " Recent Results Cancer Res. (Germany) 152:94-102, 1998.
	Scanlan et al., "Characterization of human colon cancer antigens recognized by autologous antibodies," Int. J. Cancer 76:652-658, 1998.
	Simons et al., "Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer," Cancer Research 57:1537-1546, 1997.
	Soffer et al., "Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma," Proc. Natl. Acad. Sci. U.S.A. 95:13141-13146, 1998.
	Takahashi et al., "707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma," Clin. Cancer Res. 3:1363-1370, 1997.
	Genbank Accession No. AI459806, Hillier et al., WashU-NCI human EST Project, March 9, 1999.
	Genbank Accession No. AI590782, NCI-CGAP http://www.ncbi.nih.gov/ncicgap, National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index, May 14, 1999.
	Genbank Accession No. AI115047, Marra et al., The WashU-HHMI Mouse EST Project, September 2, 1998

EXAMINER	DATE CONSIDERED
/Minh Tam Davis/	(05/11/2006)

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.